Cardiovascular Systems Financial Statements ()
|
|
|
|
Report date
|
|
|
20.08.2020 |
19.08.2021 |
31.12.2021 |
30.06.2022 |
18.08.2022 |
|
09.02.2023 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
236.5 |
259.0 |
|
236.2 |
236.2 |
|
183.7 |
|
Operating Income, bln rub |
|
|
-26.8 |
-11.9 |
|
-35.8 |
-35.8 |
|
-28.9 |
|
EBITDA, bln rub |
? |
|
-25.5 |
-10.7 |
|
-31.6 |
-34.5 |
|
-26.4 |
|
Net profit, bln rub |
? |
|
-27.2 |
-13.4 |
|
-36.9 |
-36.9 |
|
-28.2 |
|
|
OCF, bln rub |
? |
|
-12.8 |
-0.884 |
|
0.000 |
-24.3 |
|
-27.0 |
|
CAPEX, bln rub |
? |
|
4.09 |
3.95 |
|
0.000 |
4.22 |
|
3.73 |
|
FCF, bln rub |
? |
|
-16.9 |
-4.84 |
|
0.000 |
-28.5 |
|
-30.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
|
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
|
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
214.6 |
209.8 |
|
207.2 |
208.6 |
|
161.2 |
|
Cost of production, bln rub |
|
|
48.8 |
61.1 |
|
63.4 |
63.4 |
|
51.4 |
|
R&D, bln rub |
|
|
43.4 |
41.1 |
|
36.7 |
36.7 |
|
27.4 |
|
Interest expenses, bln rub |
|
|
1.97 |
1.74 |
|
0.000 |
1.63 |
|
1.22 |
|
|
Assets, bln rub |
|
|
339.5 |
352.6 |
326.4 |
0.323 |
322.7 |
|
311.5 |
|
Net Assets, bln rub |
? |
|
268.8 |
271.0 |
259.5 |
0.249 |
249.5 |
|
239.4 |
|
Debt, bln rub |
|
|
20.8 |
20.6 |
0.000 |
0.000 |
20.3 |
|
20.1 |
|
Cash, bln rub |
|
|
232.2 |
207.0 |
176.5 |
0.160 |
159.8 |
|
132.0 |
|
Net debt, bln rub |
|
|
-211.3 |
-186.4 |
-176.5 |
-0.16 |
-139.5 |
|
-111.9 |
|
|
Ordinary share price, rub |
|
|
31.6 |
42.7 |
18.8 |
14.4 |
14.4 |
|
13.6 |
|
Number of ordinary shares, mln |
|
|
34.3 |
38.8 |
|
39.2 |
39.2 |
|
39.7 |
|
|
Market cap, bln rub |
|
|
1 081 |
1 656 |
0 |
563 |
563 |
|
540 |
|
EV, bln rub |
? |
|
870 |
1 470 |
-177 |
563 |
424 |
|
428 |
|
Book value, bln rub |
|
|
252 |
256 |
243 |
0 |
234 |
|
224 |
|
|
EPS, rub |
? |
|
-0.79 |
-0.35 |
|
-0.94 |
-0.94 |
|
-0.71 |
|
FCF/share, rub |
|
|
-0.49 |
-0.12 |
|
0.00 |
-0.73 |
|
-0.78 |
|
BV/share, rub |
|
|
7.36 |
6.58 |
|
0.01 |
5.96 |
|
5.66 |
|
|
EBITDA margin, % |
? |
|
-10.8% |
-4.14% |
|
-13.4% |
-14.6% |
|
-14.3% |
|
Net margin, % |
? |
|
-11.5% |
-5.18% |
|
-15.6% |
-15.6% |
|
-15.4% |
|
FCF yield, % |
? |
|
-1.56% |
-0.29% |
0.00% |
0.00% |
-5.06% |
|
-5.69% |
|
ROE, % |
? |
|
-10.1% |
-4.95% |
0.00% |
-14 804% |
-14.8% |
|
-11.8% |
|
ROA, % |
? |
|
-8.02% |
-3.81% |
0.00% |
-11 446% |
-11.4% |
|
-9.06% |
|
|
P/E |
? |
|
-39.7 |
-123.4 |
|
-15.3 |
-15.3 |
|
-19.1 |
|
P/FCF |
|
|
-64.2 |
-342.3 |
|
|
-19.8 |
|
-17.6 |
|
P/S |
? |
|
4.57 |
6.40 |
|
2.38 |
2.38 |
|
2.94 |
|
P/BV |
? |
|
4.29 |
6.48 |
0.00 |
2 410 |
2.41 |
|
2.41 |
|
EV/EBITDA |
? |
|
-34.1 |
-137.1 |
|
-17.8 |
-12.3 |
|
-16.3 |
|
Debt/EBITDA |
|
|
8.28 |
17.4 |
|
0.01 |
4.05 |
|
4.25 |
|
|
R&D/CAPEX, % |
|
|
1 061% |
1 038% |
|
|
870.1% |
|
734.4% |
|
|
CAPEX/Revenue, % |
|
|
1.73% |
1.53% |
|
0.00% |
1.79% |
|
2.03% |
|
| Cardiovascular Systems shareholders |
